Document is current
Any future updates will be listed below
-
Authors
Ng, Szeyi https://orcid.org/0000-0002-7191-709X
Kilburn, Lucy S.
Stobart, Hilary
Stephen, Lesley
Bhattacharya, Indrani S.
Cameron, David A.
Lewis, Rebecca
McIntosh, Stuart A.
Palmieri, Carlo
Towns, Catherine
Coles, Charlotte E.
Bliss, Judith M.
- License Information
-
More Information
Article History
Received: 11 March 2025
Revised: 21 July 2025
Accepted: 2 August 2025
First Online: 19 August 2025
Competing interests
: SN is funded through CEC’s NIHR Research Professorship and Breast Cancer Now. HS reports membership of the Breast Cancer Now Tissue Bank Advisory Board and voluntary trustee membership of the Independent Cancer Patients’ Voice charity; an honorarium from the Lancet Commission funded by Breast Cancer Now and University of Cambridge; an honorarium from CRUK Precision Grand Challenge; and support for travel expenses from Breast Cancer Now, CRUK, the Association of Breast Surgeons UK, and Breast International Group. LS reports support for travel expenses from Breast Cancer Now. SAMcI reports grant funding from the NIHR, CRUK, and Breast Cancer Now; honoraria from Roche, MSD, AstraZeneca, Becton, Dickinson and Company, Exact Sciences, Veracyte; travel and conference support from Roche, Eli Lilly, Breast Cancer Now, and MSD; membership of advisory boards for Eli Lilly, MSD, Roche, and Novartis; chair of UK Breast Cancer Clinical Studies Group; and roles for the Royal College of Surgeons Breast Surgical Specialty Lead (unpaid). CEC reports grants from Breast Cancer Now, Cancer Research UK (CRUK), Addenbrooke’s Charitable Trust, and the National Institute for Health and Care Research (NIHR); participation in the PROTIS phase III sinonasal proton versus IMRT trial (member), the TORPEdO Proton Beam Therapy trial (member); and a leadership role for the Lancet Breast Cancer Commission (chair). JMB reports research grants from Breast Cancer Now, AstraZeneca, MSD, Puma Biotechnology, Clovis Oncology, Pfizer, Janssen-Cilag, Novartis, Eli Lilly, Roche, CRUK, and the NIHR. All other authors declare no competing interests.
: The study protocol was approved by the Committee for Clinical Research (Institutional Review Board at the Royal Marsden NHS Foundation Trust). Completion of the survey by the respondent is anonymous and no identifiable data will be collected about survey respondents. Completion and submission of the survey will be taken as informed consent.
